Consulting Services
For Investors
Products
Case Studies
Insights
BioPharma and Tech News

Contact Us

Search

tulisokibart

Immunology Today

Immunology Today—June 24, 2026

This week’s Immunology update highlights regulatory approvals, advancing late-…

Immunology

Immunology Weekly News - October 8th 2025

🧬 This Week in Immunology: robotic ESD milestone, pediatric AD access, in vivo…

Categories

Obesity News
Endocrinology News
Our Insights
Immunology News
Case studies
Hematology News
BioPharma and Tech News
Oncology News
BioPharma Strategy, CI and AI Guides
Lucid Diligence Brief
Conference Social Media Reports
Venture Capital Trends
AI in Healthcare and Digital Health
Conference Previews
Cell and Gene Therapy News
Healthcare and Pharma Trends
Rare Disease News
Health Mobile Apps Reports
Neuroscience News
LucidWargames
Women's Health News
Public Health News
Respiratory News
Cardiovascular News
Vaccine news

Recent Posts

Bionyra Pharma Launches With $165M to Advance Immunology Biologics | Lucid Diligence Brief
Neuroscience Today—June 24, 2026
Women’s Health Today—June 24, 2026
AbbVie’s Apogee Acquisition Valued at $10.9B. | Lucid Diligence Brief
Immunology Today—June 24, 2026

Tags

ABP-745 AMCHEPRY American Urological Association BRAIx Risk Score drug discovery partnerships EB613 ELEVATE-HFpEF ENHERTU Exosomes Eyenuk EyeArt FluoGuide Fractional Flow Reserve frexalimab G2GBIO GE HealthCare Getha IMAAVY Influenza Vaccine Intercept Pharmaceuticals K-cell technology label update Leucovorin Linerixibat LOJUXTA LUMEVOQ MB097 Metabolic Surgery mNexspike molecular glue degrader Moleculin NT-proBNP Nutrition guidelines Ocrelizumab pouchitis progressive MS Rapport Therapeutics Spinal muscular atrophy type 1 Stablepharma SVT-001 transformers AI Ultra-processed foods VALANX Biotech verapamil SR XOSPATA Xtandi

Archives

Archives

LucidQuest Ventures

Accelerate Your Success

LATEST NEWS

Bionyra Pharma Launches With $165M to Advance Immunology Biologics | Lucid Diligence Brief
Neuroscience Today—June 24, 2026
Women’s Health Today—June 24, 2026
AbbVie’s Apogee Acquisition Valued at $10.9B. | Lucid Diligence Brief
Immunology Today—June 24, 2026

TAGS

ABP-745 AMCHEPRY American Urological Association BRAIx Risk Score drug discovery partnerships EB613 ELEVATE-HFpEF ENHERTU Exosomes Eyenuk EyeArt FluoGuide Fractional Flow Reserve frexalimab G2GBIO GE HealthCare Getha IMAAVY Influenza Vaccine Intercept Pharmaceuticals K-cell technology label update Leucovorin Linerixibat LOJUXTA LUMEVOQ MB097 Metabolic Surgery mNexspike molecular glue degrader Moleculin NT-proBNP Nutrition guidelines Ocrelizumab pouchitis progressive MS Rapport Therapeutics Spinal muscular atrophy type 1 Stablepharma SVT-001 transformers AI Ultra-processed foods VALANX Biotech verapamil SR XOSPATA Xtandi

Consulting Services
For Investors
Products
Case Studies
Insights
BioPharma and Tech News

© 2026 LucidQuest Ventures. All rights reserved

We use cookies from third party services to offer you a better experience. Read about how we use cookies and how you can control them by clicking "Privacy Preferences".

Privacy Preference Center

Privacy Preferences

When you visit any website, it may store or retrieve information on your browser in the form of cookies. Since we respect your right to privacy, you can choose not to permit data collection from certain types of services. However, not allowing these services may impact your experience ans we are able to offer you.

Privacy Policy

Required

You read and agreed to our Privacy Policy

Tracking

We use third-party cookies that help us analyze and understand how you use this website. These cookies do not store any personal information.

Privacy Policy